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t all began with petunias. In the late 1980s, geneticist
Richard Jorgensen, then working at a California plant
biotechnology company, attempted to deepen the hue of
purple petunias by introducing more of the gene that gives
them their color, in the form of double-stranded RNA
(dsRNA). Instead, some of the engineered flowers became variegat-
ed and others turned white, indicating that expression of both the
introduced pigmentation gene and its homologous endogenous
gene had been knocked down or knocked out altogether. Jorgensen
had serendipitously discovered an age-old natural biologic process
now recognized to be evolutionarily conserved in most, if not all,
forms of life. Today, gene silencing—or RNA interference (RNAi),
as it is now known—has revolutionized genetics and is on the verge
of spawning an entirely new class of drugs to treat human diseases
with a genetic component.
The ability to selectively silence genes is one of the hottest topics
in biology today. Science crowned RNAi as its “Breakthrough of the
Year” in 2002. Nobel laureate and RNAi pioneer Phillip Sharp, who
is Salvador E. Luria Professor of Biology and director of the
McGovern Institute for Brain Research at the Massachusetts
Institute of Technology (MIT), calls it “the most exciting discovery
in the last decade,” adding that “there’s not an area of biological sci-
ence this will not touch.” John Maraganore, who is president, CEO,
and director of Alnylam Pharmaceuticals, touts RNAi as “presenting
perhaps the broadest new class of therapeutics since recombinant
proteins and monoclonal antibodies.”
Can RNAi live up to the hype? That remains to be seen, of
course, but academic and industrial researchers are optimistic that it
can and will, if the significant remaining barriers to its progress can
be overcome. Given the rapid pace of discovery in the field, such
optimism may well be justified.
RNA Redefined
It once seemed so simple, so straightforward: basically, DNA makes
messenger RNA (mRNA); mRNA makes proteins. But the discoveries
associated with RNAi have shown that the real story is far more com-
plex. RNA has been unveiled as the “man behind the curtain” in the
cell, wielding previously unimagined control over and influence upon
cellular processes (including gene expression and regulation) and
organism development. RNAi has been revealed to be an ancient
mechanism protecting cells from invading viruses and from damage by
transposable genetic elements, performing a variety of cellular house-
keeping functions essential to survival, health, and development.
RNAi was first described and so named by molecular biologists
Andrew Fire of the Carnegie Institute of Washington and Craig
Mello of the University of Massachusetts, along with their colleagues,
in a landmark 19 February 1998 Nature paper that electrified the
biology community. The team found that administering tiny
amounts of dsRNA to Caenorhabditis elegans resulted in potent
sequence-specific gene silencing. Tantalized by the possibility of
acquiring a powerful new tool for genetic manipulation and analysis,
investigators around the world began investigating RNAi. 
The flood of significant discoveries that followed soon estab-
lished the basic outlines of the mechanisms involved in RNAi.
Researchers using Drosophila found in 2000 that long-strand dsRNA
was processed in cells into 21- to 23-nucleotide snippets of RNA,
which then cleaved to precisely matching homologous mRNA
sequences, degrading the mRNA and effectively silencing the corre-
sponding gene by blocking its ability to encode for proteins. The
higher life forms, such as mammals, while conserving this ability, use
it in different ways; the response to dsRNA is more complicated,
triggering a cellular immune response involving the release of inter-
feron that ultimately kills the cell. 
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Then, in 2001, Thomas Tuschl, then of
the Max Planck Institute for Biophysical
Chemistry in Göttingen, Germany, discov-
ered with his colleagues that RNAi could be
prompted through the use of shorter pieces
of RNA known as small interfering RNAs
(siRNAs). Soon thereafter, they showed that
duplexes of 21-nucleotide siRNAs mediated
RNAi in cultured mammalian cells and
demonstrated that siRNAs could be
designed to silence specific genes without
activating the interferon response. In other
words, scientists could potentially silence
any gene of interest in a highly predictable,
reproducible, and accurate fashion.
Research scientist Gregory Hannon and
his colleagues at New York’s Cold Spring
Harbor Laboratory contributed several key
discoveries during the same period. They
identified, described, and named the
“Dicer” enzyme, which chops dsRNA into
siRNAs, as well as the RNA-induced silenc-
ing complex (RISC), which mediates the
silencing process by degrading the homolo-
gous mRNA. In 2002, they described the
use in mammalian cells of so-called short
hairpin RNAs (shRNAs), which generate
endogenous siRNAs within cells and thus
provide stable, heritable gene silencing (in
contrast, administered siRNAs are transient
in their silencing effect). They whimsically
named this effect “short hairpin–activated
gene silencing,” or SHAGging. This discov-
ery allowed the development of cell lines
and animal models with permanently
silenced genes—a major step forward for
basic science in general, and especially for
functional genomics. 
Further advances in the past few years
have added the ability to silence the expres-
sion of just the mutant copy of a gene, leav-
ing the normal copy intact, as well as to
modulate the level of silencing in order to
produce a range of phenotypes. Plus,
researchers can now induce silencing in a
controlled manner and target multiple
genes for silencing. These discoveries alone
are quite important—all of these capabili-
ties are crucial in a variety of critical appli-
cations. But some proponents believe this is
only the beginning, and the best may be yet
to come.
Knock Down Genes, Drag Out
Knowledge
With the continual refinement and
improvement of techniques to silence genes
with exquisite specificity, RNAi has already
had a major impact on molecular biology.
For example, the pace of discovery in func-
tional genomics has accelerated as a conse-
quence of researchers’ enhanced ability to
practice reverse genetics, in which a gene’s
function can be inferred by silencing its
expression. With complete sequences of sev-
eral genomes now on hand, including those
of C. elegans, Drosophila, the mouse, and the
human, investigators can now quickly, easi-
ly, reliably, and relatively inexpensively use
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3siRNAs to silence genes of interest and
determine their functions. Several compa-
nies are already selling made-to-order
siRNAs for use in functional genomics
work, as well as for drug target identifica-
tion and validation. 
The ability to knock down genes
either stably (that is, creating heri-
table phenotypes through
germline transmission of per-
manently silenced genes) or
transiently (as opposed to
knocking them out alto-
gether) has some impor-
tant advantages in the
production of animal
models and in vitro cell
lines. When a gene is consid-
ered silenced by RNAi, expres-
sion is typically reduced by 70% or
more. This allows the method to be used
in so-called essential genes, which cannot be
knocked out in animal models without
killing the animal. Also, “turning down” a
gene by a certain amount can sometimes
more closely resemble a disease state, allow-
ing the fashioning of more useful, refined
models of some diseases.
Russell Thomas, director of the func-
tional genomics research program at the
CIIT Centers for Health Research in
Research Triangle Park, North Carolina,
points out another advance that RNAi has
brought to animal studies: “When you
knock out a gene in mice, you have to live
with the consequences,” he says. “The tar-
geted gene is knocked out for the remain-
der of the animal’s life span. In contrast,
shRNAs with inducible promoters allow
an investigator to control the timing for
the knockdown of the targeted gene. With
this technology, you don’t have residual
developmental effects, and you can have
more sophisticated experimental designs
since you can look at wild-type expression
and knockdown in the same animal and at
multiple times throughout the animal’s
life span.” 
Sharp observes that RNAi will in some
cases obviate the need for animal knockouts.
“You can do gene knockouts in mice, and
then relate phenotype to somatic cells in the
human, but it’s very expensive, the gene has
to be nonessential to get an interesting phe-
notype, and you have to ask the question in
the context of the developing mouse,” he
says. By comparison, he explains, RNAi
allows researchers to inactivate the gene and
observe in real time the changes in the meta-
bolic, cell biologic, or other phenotype of
the cell, and characterize the role of the gene
in that particular situation.
Although these applications of RNAi
are not yet perfected and are unlikely to
completely replace classic knockout studies,
many scientists are excited about adding
these new capabilities and efficiencies to
their bag of laboratory tricks. “It’s funda-
mentally changing how we
do laboratory science,” says
Sharp. “It will change how we
do animal genetics, and we have
not even scratched the surface of all
the ways it will be used.” 
RNAi and the Big Picture
The ability to reproducibly and robustly
silence every single gene in the genome is
expected to facilitate the acquisition of pro-
found new knowledge regarding function
and regulation at the cell and whole-organ-
ism levels. Several organizations are in the
process of constructing large-scale RNAi
libraries that should be available for use
very soon. 
Genomewide screening using RNAi
libraries will help researchers learn more
about global questions in systems biology,
elucidating the nature and role of the com-
plex, often interrelated pathways and signal-
ing networks at work in organisms.
Leona Samson, director of the MIT
Center for Environmental Health Sci-
ences, has already used such a library for
the 4,800 nonessential genes in Saccharo-
myces cerevisiae. She says that higher-
organism RNAi construct libraries will aid
toxicogenomics research by allowing
researchers to interrogate each and every
gene of an organism—to examine a specif-
ic gene to determine its function, or to
screen large amounts of genes in the con-
text of a specific function, to see which
ones contribute to the function, and pos-
sibly what roles they might play and how
they might interact. As a result, Samson
says, “you can start to identify the impor-
tant pathways for helping cells recover
from toxic insults.” 
Samson says there are important toxi-
cogenomics treatment and prevention end
points to be achieved with this type of
large-scale screening. By interrogating
every gene, it’s possible to compile a por-
trait of all the pathways that are relevant to
cellular function and response, such
that researchers could look at
which genes are being
expressed in members of a
population and accurate-
ly predict the effects of
exposure to particular
environmental agents.
“In the end,” Samson
says, “we’re going to get
an integrated systems
view, and we need that to be
able to make predictions.”
There’s More to the Machinery
It  turns out that gene silencing through
degradation of mRNA by siRNAs is not the
only cellular mechanism regulated by small
pieces of RNA. Thanks to groundbreaking
work in C. elegans, researchers have discov-
ered a class of natural small RNA molecules
called microRNAs that appear to be crucial
in regulating development. Although they
apparently use the same tools as siRNAs to
carry out their functions—Dicer, RISC, and
a family of proteins known as Argonautes—
microRNAs differ in that their sequences do
not precisely match their mRNA targets. As
such, they regulate the expression of pro-
teins by those targets, rather than degrade
them altogether, which leads investigators to
believe that they play an important role in
the timing and nature of development—
perhaps to the point of controlling differen-
tiation in embryonic stem cells. 
At Sharp’s lab, researchers discovered a
set of microRNA genes that are expressed
exclusively in embryonic stem cells. “As far as
we can tell,” Sharp says, “they’re shut off as
soon as those cells undergo differentiation.
So we’re interested in what function those
RNAs would have in the embryonic stem
cell. And we’re also interested in devising
ways to understand the specificity by which
microRNAs regulate their targets.” Further,
according to Sharp, it is important to eluci-
date exactly how a microRNA interacts with
a target RNA to regulate transcription. 
Tuschl, who is now group leader of the
Laboratory of RNA Molecular Biology at
Rockefeller University, says, “It’s a very com-
plicated regulatory machinery that you have
in your cells, with a very complicated biolo-
gy behind it. We know that there are genes
that express dsRNA and microRNAs, and
that this gene family in humans is about
250 genes, and many of these genes are con-
served. . . . The question is what all these
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[RNAi is] fundamentally changing how we
do laboratory science. It will change how
we do animal genetics, and we have
not even scratched the surface
of all the ways it will be used.
–Phillip Sharp
Massachusetts Institute of Technologygenes are doing, and how the RNAi
machinery ties in to the gene regulation
mediated by the microRNA genes.”
Recent studies further suggest there is yet
a third mechanism controlled by micro-
RNAs, an arm of the silencing machinery in
the nucleus of the cell that modifies hete-
rochromatin. The result is transcriptional
repression of gene expression. 
As Tuschl puts it, “This is one of the
real highlights of the discovery of RNAi—
that it’s a new cellular mechanism involved
in regulating gene expression, and it’s as
complicated and as effective as transcrip-
tional gene regulation.” More thorough
understanding of this mechanism could
eventually lead to beneficial insights into
development and disease processes, partic-
ularly carcinogenesis. 
Silencing Disease
Although biologists are excited about the
long-range additions to knowledge
that could emerge from studying
the complexities of the RNAi
machinery, many are focus-
ing major efforts on ex-
ploiting what is already
known—that the gene-
silencing effect of RNAi
holds tremendous prom-
ise in treating human
disease. 
RNAi therapeutics will
be judged on the same criteria
as any other prospective drug:
potency, stability, and safety. Despite
the great deal of work yet to be done, many
researchers believe that RNAi-based agents
will eventually pass muster on those issues,
and will actually have inherent advantages
over presently available classes of drugs. 
For example, the fact that RNAi is a
natural cellular process may mean that
drugs based upon the phenomenon can be
expected to be quite efficacious. “The
siRNA process depends upon the endoge-
nous pathway of microRNA biology, a
process that’s present in all cells,” says
Sharp. “Therefore, it’s efficient, it’s a nor-
mal biological process, and we are learning
how to design siRNAs that are more effi-
ciently taken up in that process and more
efficiently used in silencing.” 
Maraganore agrees. “What’s very
unique about RNAi is that it’s the first
natural mechanism that’s ever been discov-
ered that would allow people to silence
genes,” he says. “Because of that leveraging
of that natural mechanism, you have a
high degree of specificity and potency in
the action of siRNAs.” 
According to Nassim Usman, chief
operating officer and senior vice president
of Sirna Therapeutics in Boulder, Colo-
rado, there is ample precedent for this
opinion. “If you look at the history of suc-
cessful biotechnology drugs, a lot of them
that have been successful are the ones that
either use or replace a naturally occurring
mechanism,” he says. “The two clearest
examples are recombinant proteins and
antibodies.”
The potential therapeutic value of
RNAi has been repeatedly demonstrated
in a wide variety of in vitro studies, and
more and more in vivo experiments are
confirming that early promise. Efficacy in
gene silencing has been shown in viral dis-
eases (such as HIV/AIDS, influenza,
human papillomavirus infection, various
hepatitis strains, smallpox, and SARS),
neurodegenerative diseases (such as
Parkinson disease, amyotrophic lateral
sclerosis, and Alzheimer
disease), cancer, inflammato-
ry diseases (such as rheumatoid
arthritis), and autoimmune dis-
eases (such as type 1 diabetes melli-
tus). The intense interest in RNAi
therapeutics has come at least in part
because of its potential broad applicability
across such a wide spectrum of disorders. 
Researchers also cite the specificity of
RNAi targeting: siRNAs may be able to
effectively reach cellular targets that have
previously been inaccessible or highly resist-
ant to other forms of therapy. Success in
reaching such targets could lead to signifi-
cant advances in the treatment of several dis-
eases with currently unmet medical needs. 
The Principle of the Thing
Researchers in academic and industrial labs
around the world are pursuing therapeutic
applications of RNAi. One good illustration
is the work conducted by senior investigator
and associate pediatrics professor Judy
Lieberman and her group at the Institute for
Biomedical Research of the Harvard Med-
ical School Center for Blood Research. 
In 2003, the team published two RNAi
studies of landmark importance. In one, an
in vitro experiment presented in the Journal
of Virology in July 2003 (issue 13), the team
achieved sustained siRNA-mediated silenc-
ing of HIV-1 in primary macrophages, in
essence preventing infection from taking
hold. In previous studies conducted in rap-
idly dividing cells, such as tumors, the RNAi
effect lasted only 3–5 days. In these macro-
phages, however, as Lieberman explains,
“the silencing lasted very long, in fact for as
long as we could keep the cultures growing,
for some genes.” 
The experiment co-targeted the viral
p24 structural gene and CCR5, the major
HIV-1 co-receptor in macrophages, cells
that are known to be reservoirs of HIV
infection and that are stubbornly resistant to
current antiviral therapies. The team found
that they could completely suppress
HIV replication in macrophages
by using this co-targeting strat-
agem. They also found that
they could inhibit viral
replication in cells that
were already infected, in
which HIV was integrat-
ed into the host cell. As
Lieberman summarized,
those are “pretty encourag-
ing data for the possibility of
using siRNA against HIV.”
The experiment also showed that
RNAi holds promise as an antiviral
treatment by silencing both host cell recep-
tors and viral replication genes.
In the other major study, published in
the March 2003 issue of Nature Medicine,
Lieberman and her colleagues demonstrated
that RNAi could effectively treat or prevent
disease in vivo. They successfully prevented
liver failure and fibrosis in two mouse mod-
els of autoimmune hepatitis by silencing the
Fas gene, which encodes the Fas receptor.
Many liver diseases are characterized by
apoptosis, which is mediated by the Fas pro-
tein. “It turns out that the liver damage in a
lot of kinds of hepatitis—even environmen-
tally caused hepatitis, such as from alcohol
or carbon tetrachloride exposure—all goes
through the same final pathway,” says
Lieberman. “Hepatitis B and C are not
pathogenic viruses. It’s really the immune
cells that infiltrate into the liver that become
activated, engage the receptor that’s
expressed on liver cells, and trigger death.” 
The group of mice treated with the Fas
siRNA were protected when challenged
with a hepatitis-inducing agent, and in a
related experiment, most of the animals in
the treated group were cured after having
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This is one of the real highlights of
the discovery of RNAi—that it’s a
new cellular mechanism involved in
regulating gene expression, and
it’s as complicated and as effective
as transcriptional gene regulation.
–Thomas Tuschl
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been subjected to a particularly aggressive
model of hepatitis. “The results were pretty
dramatic,” says Lieberman, “and they were
obtained without any optimization.” With
these and similar results reported by other
investigators, it’s not surprising that hepati-
tis is one of the initial treatment targets
being pursued by RNAi biotechnology
companies.
With a $12 million grant from the
National Institute of Allergy and Infectious
Diseases, Lieberman’s group, along with col-
leagues at MIT, is also studying the potential
application of RNAi as a weapon against
bioterrorism. The four projects funded by
the grant include one led by Sharp to probe
how RNAi and viral infection interact,
another led by Lieberman designed to look
at delivery questions, a third led by MIT
assistant immunology professor Luk van
Parijs looking at the effects of silencing vari-
ous immune genes, and a fourth led by
Harvard assistant pediatrics professor Prem-
lata Shankar looking specifically at the pos-
sible application of RNAi against viral
bioterrorism agents such as flaviviruses and
poxviruses.
Successful proof-of-principle studies are a
long way from proven clinical safety and effi-
cacy, of course, but academic and industrial
researchers alike are confident that RNAi
therapies will move rapidly from bench to
bedside. Usman says Sirna expects to file an
investigational new drug application with
the U.S. Food and Drug Administration for
an siRNA-based drug for age-related macular
degeneration later this year. That would be a
remarkable milestone, considering that the
RNAi phenomenon itself has only been rec-
ognized for six years.
The rapid pace of discovery and devel-
opment of RNAi therapeutics should con-
tinue, according to Maraganore. “It’s a
technology that, while early in terms of its
discovery, lends itself to a very rapid cycle
from target identification to lead optimiza-
tion all the way through the start of formal
investigational new drug–enabling studies,”
he says. 
Delivery, Delivery, Delivery
Delivery—getting those exquisitely specific
siRNAs or shRNAs to the appropriate sites
in the appropriate amounts to ensure appro-
priate uptake and the intended silencing—
remains a considerable challenge. Experts in
the field agree that delivery is a daunting bar-
rier to successful RNAi therapy. However,
RNAi biotech companies and their backers
are banking on overcoming the delivery bar-
rier, and academic researchers seem confi-
dent that it can be done. 
As Tuschl explains, there are basically
two strategies for delivering siRNAs in vivo.
One strategy is gene therapy, which uses a
viral vector to deliver the siRNA to the cells
of interest. The other route is the chemical
synthesis of the reagent, using some chemi-
cal modifications that change the properties
of the siRNA such that they are more stable
and are retained longer in the bloodstream;
this simultaneously changes their uptake
properties and allows more opportunity for
uptake. With the broad applicability of
RNAi to a diverse range of human diseases
in a wide variety of organ systems, both
delivery methods are being pursued for spe-
cific therapeutic targets.
As RNAi therapies make their way into
the clinic, it is perhaps inevitable that a more
traditional dichotomy will emerge in deliv-
ery: local versus systemic administration.
Some organs are simply much easier than
others to reach with drugs. Says Maraganore,
“The delivery hurdles are going to be more
significant for systemic uses of RNAi—in
other words, administration of siRNAs
either intravenously or subcutaneously—as
compared to an approach we call direct
RNAi, which is the application of siRNAs to
certain anatomical sites, for example the eye
or the central nervous system.” With direct
RNAi, drugs can perform their actions at
such sites without having to negotiate the
gastrointestinal tract or other hurdles that
must be faced to reach less accessible organs.
Maraganore believes direct RNAi will be
the first approach to yield candidates that
are ultimately approved, followed shortly
thereafter by approaches that use systemic
administration.
The eye has been one of the first targets
of siRNA therapeutics in development.
Local delivery of an siRNA to the eye via
intravitreal injection or topical administra-
tion is aimed at controlling the proliferation
of abnormal blood vessels associated with
one form of age-related macular degenera-
tion. Several RNAi biotech companies are
working on siRNAs designed to block the
vascular endothelial growth factor pathway, a
validated target of therapy in this disease.
With the liver being another relatively easy
drug delivery site, other companies are also
in hot pursuit of an siRNA candidate com-
pound to treat hepatitis C. Alnylam, mean-
while, is collaborating with the Mayo Clinic
to develop an siRNA targeting the gene that
encodes for α-synuclein, a protein recently
discovered by the Mayo Clinic and the NIH
to be overexpressed in people with Parkinson
disease and thought to be a causative factor
in the disease. The RNAi therapy would be
delivered to the central nervous system by
catheterization, another local delivery option
in certain situations. 
In terms of systemic delivery of RNAi
therapeutic agents, some researchers believe
DNA-based vectors will be the way to go.
Australia’s Benitec, for example, has devel-
oped a technique it has dubbed “DNA-
directed RNAi,” which it claims allows for
the inducible transient or permanent silenc-
ing of multiple genes. That approach could
prove beneficial in the treatment of diseases
such as HIV/AIDS and cancer, in which
combination therapy attacking multiple tar-
gets simultaneously is an accepted therapeu-
tic stratagem. Given the spotty track record
and regulatory scrutiny of gene therapy,
however, other developers are hitching their
wagons to the refinement of siRNAs them-
selves as drugs. 
Caution Signs
Optimism about the vast potential of RNAi
must, of course, be mitigated by the appro-
priate scientific reserve. At least some of the
delivery hurdles could yet prove to be
intractable. There could be unanticipated
off-target effects, in which an siRNA
knocks down unintended genes, potentially
provoking a toxic release of interferon. 
However,  experts such as Lieberman,
while recognizing that “things in biology
have a way of becoming more complicated
than anyone can foresee,” seem confident
that obstacles in RNAi’s path to the clinic can
be overcome. “In the last six months,” says
Lieberman, “some of the most optimistic
views of RNAi—that it was completely spe-
cific, that it wouldn’t activate interferon—
have turned out to not be absolutely true.
But I still don’t think that they’re going to be
serious problems in vivo.” Drug discovery
and development experts point out that
phenomena that might raise safety concerns
in vitro often do not turn out to be clinical-
ly significant. 
Today, RNAi is already an accepted and
vital tool of the science trade, yielding
important new knowledge day in and day
out. In medicine, RNAi is still in its infancy,
but is rising just over the horizon as one of
the first tangible and widespread benefits to
be derived from the sequencing of the
human genome. 
Aside from the potential of RNAi to
benefit human health, scientists are also
looking at the prospective ability of the tech-
nology to silence genes in economically
important plant and animal species. For
example, Japanese researchers reported in
the 19 June 2003 issue of Nature the suc-
cessful construction of transgenic coffee
plants that are naturally decaffeinated by
knocking down a gene involved in caffeine
biosynthesis.
Now if they could just do something
about those washed-out petunias . . . 
Ernie Hood
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